Literature DB >> 12016426

Hepatocellular carcinoma: diagnosis and treatment.

Alex S Befeler1, Adrian M Di Bisceglie.   

Abstract

Hepatocellular carcinoma is the most frequent primary malignancy of the liver and appears to be rising in incidence in the United States and other developed western countries. Imaging studies play a key role in diagnosis of hepatocellular carcinoma, and more and more commonly, patients are being diagnosed at an asymptomatic stage. The use of triphasic computed tomography scanning and improved magnetic resonance imaging equipment and protocols has led to greater sensitivity and specificity for these techniques in diagnosis of hepatocellular carcinoma. Accurate staging of hepatocellular carcinoma is important in determining prognosis and in helping decide the best treatment for each patient. No one staging system appears optimal, but important factors to be considered are the size of the tumor, severity of underlying liver disease, and the functional status of the patient. Liver transplantation has grown in importance as a treatment for hepatocellular carcinoma but may be limited by availability of donor organs and long waiting times. This situation may be improved by greater use of living donor liver transplantation. Hepatic resection remains an important treatment modality for hepatocellular carcinoma, particularly in the absence of cirrhosis. Tumor ablation by alcohol injection or radiofrequency ablation is associated with favorable outcomes and may be considered a potentially curative treatment. Early diagnosis of hepatocellular carcinoma remains a key goal in improving the poor prognosis of this form of liver cancer. Identifying hepatocellular carcinoma at an early stage is often associated with having better treatment options for patients with small, asymptomatic tumors.

Entities:  

Mesh:

Year:  2002        PMID: 12016426     DOI: 10.1053/gast.2002.33411

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  153 in total

1.  Functional magnetic resonance imaging response of targeted tumor burden and its impact on survival in patients with hepatocellular carcinoma.

Authors:  Celia Pamela Corona-Villalobos; Vivek Gowdra Halappa; Susanne Bonekamp; John Eng; Diane Reyes; David Cosgrove; Neda Rastegar; Li Pan; Timothy M Pawlik; Ihab R Kamel
Journal:  Invest Radiol       Date:  2015-04       Impact factor: 6.016

Review 2.  Hepatocellular carcinoma: updates in primary prevention.

Authors:  Will J Fecht; Alex S Befeler
Journal:  Curr Gastroenterol Rep       Date:  2004-02

Review 3.  Diagnostic biopsy for hepatocellular carcinoma in cirrhosis: useful, necessary, dangerous, or academic sport?

Authors:  J Schölmerich; D Schacherer
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

4.  Radiofrequency ablation in the treatment of small hepatocellular carcinoma: a meta analysis.

Authors:  Jun-Guo Liu; Yi-Jun Wang; Zhi Du
Journal:  World J Gastroenterol       Date:  2010-07-21       Impact factor: 5.742

5.  Preoperative Controlling Nutritional Status plus Tumor Burden Score for the Assessment of Prognosis after Curative Liver Resection for Hepatocellular Carcinoma.

Authors:  Yasuyuki Fukami; Takuya Saito; Takaaki Osawa; Takashi Arikawa; Tatsuki Matsumura; Shintaro Kurahashi; Shunichiro Komatsu; Kenitiro Kaneko; Tsuyoshi Sano
Journal:  Med Princ Pract       Date:  2020-12-24       Impact factor: 1.927

6.  Poor prognosis for hepatocellular carcinoma with transarterial chemoembolization pre-transplantation: retrospective analysis.

Authors:  Hai-Lin Li; Wen-Bin Ji; Rui Zhao; Wei-Dong Duan; Yong-Wei Chen; Xian-Qiang Wang; Qiang Yu; Ying Luo; Jia-Hong Dong
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

7.  Decreased aquaporin expression leads to increased resistance to apoptosis in hepatocellular carcinoma.

Authors:  Elizabeth M Jablonski; M Adrian Mattocks; Eugene Sokolov; Leonidas G Koniaris; Francis M Hughes; Nelson Fausto; Robert H Pierce; Iain H McKillop
Journal:  Cancer Lett       Date:  2006-11-03       Impact factor: 8.679

8.  Interleukin-6 mediates G(0)/G(1) growth arrest in hepatocellular carcinoma through a STAT 3-dependent pathway.

Authors:  Dairmuid M Moran; M Adrian Mattocks; Paul A Cahill; Leonidas G Koniaris; Iain H McKillop
Journal:  J Surg Res       Date:  2007-06-14       Impact factor: 2.192

9.  LncRNA WWOX-AS1 sponges miR-20b-5p in hepatocellular carcinoma and represses its progression by upregulating WWOX.

Authors:  Dafeng Xu; Xiangmei Liu; Jincai Wu; Yu Wang; Kailun Zhou; Wenmei Chen; Jiacheng Chen; Cheng Chen; Liang Chen
Journal:  Cancer Biol Ther       Date:  2020-09-15       Impact factor: 4.742

10.  Tumor ablation therapy of liver cancers with an open magnetic resonance imaging-based navigation system.

Authors:  Takashi Maeda; Jaesung Hong; Kozo Konishi; Takanori Nakatsuji; Takefumi Yasunaga; Yo-ichi Yamashita; Akinobu Taketomi; Kazuhiro Kotoh; Munechika Enjoji; Hideaki Nakashima; Kazuo Tanoue; Yoshihiko Maehara; Makoto Hashizume
Journal:  Surg Endosc       Date:  2008-09-24       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.